Sergei Vakulenko

Dr. Sergei Vakulenko

Department Department of Chemistry and Biochemistry, University of Notre Dame

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
NANuno T. Antunes
Nuno T. Antunes
TLToni L. Lamoureaux
Toni L. Lamoureaux
MTMarta Toth
Marta Toth
NSNichole K. Stewart
Nichole K. Stewart
HFHilary Frase
Hilary Frase
Sergei VakulenkoSergei Vakulenko
Sergei Vakulenko
Carbapenem-hydrolyzing class D β-lactamases (CHDLs) are enzymes of the utmost clinical importance due to their ability to produce resistance to carbapenems, the antibiotics of last resort for the treatment of various life-threatening infections. The vast majority of these enzymes have been identified in Acinetobacter spp., notably in Acinetobacter baumannii . The OXA-2 and OXA-10 enzymes predominantly occur in Pseudomonas aeruginosa and are currently classified as narrow-spectrum class D β-lactamases. Here we demonstrate that when OXA-2 and OXA-10 are expressed in Escherichia coli strain JM83, they produce a narrow-spectrum antibiotic resistance pattern. When the enzymes are expressed in A. baumannii ATCC 17978, however, they behave as extended-spectrum β-lactamases and confer resistance to carbapenem antibiotics. Kinetic studies of OXA-2 and OXA-10 with four carbapenems have demonstrated that their catalytic efficiencies with these antibiotics are in the same range as those of some recognized class D carbapenemases. These results are in disagreement with the classification of the OXA-2 and OXA-10 enzymes as narrow-spectrum β-lactamases, and they suggest that other class D enzymes that are currently regarded as noncarbapenemases may in fact be CHDLs.

1 September 2013 in Chemistry & Biology
Verified
Journal Article
Closed access
CSClyde Smith
Clyde Smith
NANuno Tiago Antunes
Nuno Tiago Antunes
NSNichole K. Stewart
Nichole K. Stewart
MTMarta Toth
Marta Toth
MKMalika Kumarasiri
Malika Kumarasiri
Sergei VakulenkoSergei Vakulenko
Sergei Vakulenko

9 November 2015 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
MTMarta Toth
Marta Toth
NANuno Tiago Antunes
Nuno Tiago Antunes
NSNichole K Stewart
Nichole K Stewart
HFHilary Frase
Hilary Frase
MBMonolekha Bhattacharya
Monolekha Bhattacharya
Sergei VakulenkoSergei Vakulenko
Sergei Vakulenko
Characterization of the first class D β-lactamases in Gram-positive bacteria, including the Bacillaceae family, shows that one, BPU-1, is capable of hydrolyzing a wide variety of β-lactam antibiotics and has a unique substrate-binding mode. Production of β-lactamases of one of four molecular classes (A, B, C and D) is the major mechanism of bacterial resistance to β-lactams, the largest class of antibiotics, which have saved countless lives since their inception 70 years ago. Although several hundred efficient class D enzymes have been identified in Gram-negative pathogens over the last four decades, none have been reported in Gram-positive bacteria. Here we demonstrate that efficient class D β-lactamases capable of hydrolyzing a wide array of β-lactam substrates are widely disseminated in various species of environmental Gram-positive organisms. Class D enzymes of Gram-positive bacteria have a distinct structural architecture and employ a unique substrate-binding mode that is quite different from that of all currently known class A, C and D β-lactamases. These enzymes thus constitute a previously unknown reservoir of novel antibiotic-resistance enzymes.

1 October 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HFHilary Frase
Hilary Frase
QSQicun Shi
Qicun Shi
STSebastian A. Testero
Sebastian A. Testero
SMShahriar Mobashery
Shahriar Mobashery
Sergei VakulenkoSergei Vakulenko
Sergei Vakulenko
A major mechanism of bacterial resistance to β-lactam antibiotics (penicillins, cephalosporins, carbapenems, etc.) is the production of β-lactamases. A handful of class A β-lactamases have been discovered that have acquired the ability to turn over carbapenem antibiotics. This is a disconcerting development, as carbapenems are often considered last resort antibiotics in the treatment of difficult infections. The GES family of β-lactamases constitutes a group of extended spectrum resistance enzymes that hydrolyze penicillins and cephalosporins avidly. A single amino acid substitution at position 170 has expanded the breadth of activity to include carbapenems. The basis for this expansion of activity is investigated in this first report of detailed steady-state and pre-steady-state kinetics of carbapenem hydrolysis, performed with a class A carbapenemase. Monitoring the turnover of imipenem (a carbapenem) by GES-1 (Gly-170) revealed the acylation step as rate-limiting. GES-2 (Asn-170) has an enhanced rate of acylation, compared with GES-1, and no longer has a single rate-determining step. Both the acylation and deacylation steps are of equal magnitude. GES-5 (Ser-170) exhibits an enhancement of the rate constant for acylation by a remarkable 5000-fold, whereby the enzyme acylation event is no longer rate-limiting. This carbapenemase exhibits kcat/Km of 3 × 105 m−1s−1, which is sufficient for manifestation of resistance against imipenem.

21 December 2018 in mBio
Verified
Journal Article
Open access
PDF file
MTMarta Toth
Marta Toth
NSNichole K. Stewart
Nichole K. Stewart
CSClyde Smith
Clyde Smith
Sergei VakulenkoSergei Vakulenko
Sergei Vakulenko
Clostridium difficile is the causative agent of the deadly C. difficile infection. Resistance of the pathogen to β-lactam antibiotics plays a major role in the development of the disease, but the mechanism of resistance is currently unknown. We discovered that C. difficile encodes class D β-lactamases, i.e., CDDs, which are intrinsic to this species. We studied two CDD enzymes, CDD-1 and CDD-2, and showed that they display broad-spectrum, high catalytic efficiency against various β-lactam antibiotics, including penicillins and expanded-spectrum cephalosporins. We demonstrated that the cdd genes are poorly expressed under the control of their own promoters and contribute only partially to the observed resistance to β-lactams. However, when the cdd1 gene was expressed under the control of efficient promoters in the antibiotic-sensitive Clostridium cochlearium strain, it produced high-level resistance to β-lactams. Taken together, the results determined in this work demonstrate the existence in C. difficile of intrinsic class D β-lactamases which constitute a reservoir of highly potent enzymes capable of conferring broad-spectrum, clinically relevant levels of resistance to β-lactam antibiotics. This discovery is a significant contribution to elucidation of the mechanism(s) of resistance of the clinically important pathogen C. difficile to β-lactam antibiotics. IMPORTANCEC. difficile is a spore-forming anaerobic bacterium which causes infection of the large intestine with high mortality rates. The C. difficile infection is difficult to prevent and treat, as the pathogen is resistant to many antimicrobial agents. Prolonged use of β-lactam antibiotics for treatment of various infectious diseases triggers the infection, as these drugs suppress the abundance of protective gut bacteria, allowing the resistant C. difficile bacteria to multiply. While resistance of C. difficile to β-lactam antibiotics plays the major role in the development of the disease, the mechanism of resistance is unknown. The significance of our research is in the discovery in C. difficile of β-lactamases, enzymes that destroy β-lactam antibiotics. These findings ultimately can help to combat deadly C. difficile infections.

14 December 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MTMarta Toth
Marta Toth
CSClyde Smith
Clyde Smith
HFHilary Frase
Hilary Frase
SMShahriar Mobashery
Shahriar Mobashery
Sergei VakulenkoSergei Vakulenko
Sergei Vakulenko